Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Epidemic Kaposi's sarcoma.

R L Krigel1, A E Friedman-Kien

  • 1Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111.

Seminars in Oncology
|June 1, 1990
PubMed
Summary
This summary is machine-generated.

Current treatments offer limited survival benefits for epidemic Kaposi sarcoma (KS). Antitumor therapy is palliative, with prognosis depending on HIV/immune status, not tumor load.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Culture of adult human skin: in vitro growth and keratinization of epidermal cells.

Nature·2010
Same author

The consequences of treatment and disease in patients with primary CNS non-Hodgkin's lymphoma: cognitive function and performance status. North Central Cancer Treatment Group.

Neuro-oncology·2001
Same author

Kaposi's sarcoma-associated herpesvirus can productively infect primary human keratinocytes and alter their growth properties.

Journal of virology·2001
Same author

Topical treatment of cutaneous lesions of acquired immunodeficiency syndrome-related Kaposi sarcoma using alitretinoin gel: results of phase 1 and 2 trials.

Archives of dermatology·2000
Same author

Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin Gel North American Study Group.

Journal of acquired immune deficiency syndromes (1999)·2000
Same author

A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group.

AIDS (London, England)·1999
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Area of Science:

  • Oncology
  • Immunology
  • Infectious Diseases

Background:

  • Epidemic Kaposi sarcoma (KS) is an AIDS-defining malignancy.
  • Current therapeutic options have shown limited impact on patient survival.

Purpose of the Study:

  • To evaluate the efficacy of available treatments for epidemic Kaposi sarcoma.
  • To define the prognostic factors influencing survival in patients with epidemic KS.

Main Methods:

  • Review of existing treatment modalities for epidemic KS.
  • Analysis of factors affecting patient prognosis, including immune suppression and HIV viral load.

Main Results:

  • No significant impact of available treatments on survival has been demonstrated.

Related Experiment Videos

  • Prognosis is primarily determined by the severity of immune suppression and HIV infection, not tumor burden.
  • Complete therapeutic response is challenging, often necessitating maintenance therapy.

    • Conclusions:

    • Antitumor therapy for epidemic KS should be considered palliative.
    • Advanced disease requires systemic treatment with active agents.
    • Future ideal treatment involves a combination of antiretroviral therapy, biological therapy, chemotherapy, and hematopoietic growth factors.